Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

A Systematic Integration of Current Evidence on the Role of Error-Related Negativity as a Biomarker in Psychopathology using Pairwise and Network Meta-Analyses

View through CrossRef
This meta-analysis integrates data from 139 studies involving 10,084 participants, identified through a systematic literature search, to examine neural error processing across various mental disorders—including obsessive-compulsive disorder (OCD), anxiety disorders, depressive disorders (MDD), attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), substance-related and addictive disorders (SUD), and psychotic disorders. Using pairwise and network meta-analyses, we identified robust alterations in error-related brain responses measured by the error-related negativity (ERN). OCD (g = -0.43) and anxiety disorders (g = -0.23) exhibited heightened error-related neural responses (larger ERN), whereas ADHD (g = 0.26), ASD (g = 0.30), and psychotic disorders (g = 0.67) demonstrated blunted responses (smaller ERN). No significant differences in ERN were detected in MDD (g = 0.00) or SUD (g = 0.00) overall. Patients with psychotic disorders exhibited the greatest blunting of error processing, while those with OCD showed the strongest amplification—both significantly differing from healthy participants and all other clinical groups. These findings support the transdiagnostic potential of the ERN as a reliable neurocognitive marker. ERN alterations in anxiety disorders, OCD, and psychotic disorders may serve as endophenotypes or neural risk markers that precede symptom onset and offer predictive validity, aligning with established endophenotype criteria. Increased ERN signals may reflect amplified prediction errors, leading to over-control and risk-avoidant behaviors, while decreased ERN responses indicate hypoactive error processing, impairing adaptive responses to errors and feedback. Overall, ERN alterations hold promise as biomarkers of cognitive control dysregulation, with important implications for personalized interventions and early risk detection.
Title: A Systematic Integration of Current Evidence on the Role of Error-Related Negativity as a Biomarker in Psychopathology using Pairwise and Network Meta-Analyses
Description:
This meta-analysis integrates data from 139 studies involving 10,084 participants, identified through a systematic literature search, to examine neural error processing across various mental disorders—including obsessive-compulsive disorder (OCD), anxiety disorders, depressive disorders (MDD), attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), substance-related and addictive disorders (SUD), and psychotic disorders.
Using pairwise and network meta-analyses, we identified robust alterations in error-related brain responses measured by the error-related negativity (ERN).
OCD (g = -0.
43) and anxiety disorders (g = -0.
23) exhibited heightened error-related neural responses (larger ERN), whereas ADHD (g = 0.
26), ASD (g = 0.
30), and psychotic disorders (g = 0.
67) demonstrated blunted responses (smaller ERN).
No significant differences in ERN were detected in MDD (g = 0.
00) or SUD (g = 0.
00) overall.
Patients with psychotic disorders exhibited the greatest blunting of error processing, while those with OCD showed the strongest amplification—both significantly differing from healthy participants and all other clinical groups.
These findings support the transdiagnostic potential of the ERN as a reliable neurocognitive marker.
ERN alterations in anxiety disorders, OCD, and psychotic disorders may serve as endophenotypes or neural risk markers that precede symptom onset and offer predictive validity, aligning with established endophenotype criteria.
Increased ERN signals may reflect amplified prediction errors, leading to over-control and risk-avoidant behaviors, while decreased ERN responses indicate hypoactive error processing, impairing adaptive responses to errors and feedback.
Overall, ERN alterations hold promise as biomarkers of cognitive control dysregulation, with important implications for personalized interventions and early risk detection.

Related Results

Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
This review summarizes the evidence from six randomized controlled trials that judged the effectiveness of systematic review summaries on policymakers' decision making, or the most...
The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma
The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma
Introduction Measurable residual disease (MRD) technologies have greatly enhanced our ability to guide treatment duration and predict outcome in various hematologic malignancies. H...
Transdiagnostic MRI Markers of Psychopathology following Traumatic Brain Injury: A Systematic Review
Transdiagnostic MRI Markers of Psychopathology following Traumatic Brain Injury: A Systematic Review
Background: The neural underpinnings of psychopathology following moderate-severe traumatic brain injury (TBI) remain poorly understood. Previous reviews have found limited and inc...
Cometary Physics Laboratory: spectrophotometric experiments
Cometary Physics Laboratory: spectrophotometric experiments
<p><strong><span dir="ltr" role="presentation">1. Introduction</span></strong&...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top